ClinicalTrials.gg
CompletedNCT00725985ORACLE MSUpdated Mar 22, 2021Results posted

Oral Cladribine in Early Multiple Sclerosis (MS)

A Phase 3 interventional study of Cladribine and Placebo in Multiple Sclerosis, sponsored by EMD Serono Research & Development Institute, Inc.. Completed at 158 sites in 34 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-03-22.

Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
617
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing cladribine in Multiple Sclerosis — 2 open to participants now, 5 under way, 2 of them phase 3. Cladribine · Multiple Sclerosis.

Enrollment
Largest of 14
617 · median 196
Started
2008
with 1 other
Phase 3
2 of 14
none open now
Registered
2nd of 14
by date
Lead sponsor
2 of 14
EMD Serono Research & Development Institute, Inc.

Among the 14 studies testing cladribine in Multiple Sclerosis, this one has the largest enrollment, is one of 2 that started in 2008, is one of 2 in phase 3, and was the 2nd registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 14 studies testing cladribine in Multiple Sclerosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cladribine

Cladribine: first FDA approval 1993 (LEUSTATIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing cladribine in Multiple Sclerosis, or all of them as a file.
02

Study summary

A randomized, double-blind, clinical trial to assess the safety and efficacy of two doses of oral cladribine versus placebo in participants who had a first clinical demyelinating event (clinically isolated syndrome). Participants in either the cladribine or placebo group may also enter treatment periods with open-label interferon-beta or open-label cladribine depending upon the disease status. The primary objective of this study is to evaluate the effect of two dosage regimens of oral cladribine versus placebo on the time to conversion to multiple sclerosis (MS) (from randomization) according to the Poser criteria in participants with first clinical demyelinating event at high risk of converting to MS.

Read the detailed description

This will be a randomized, double blind, three-arm, placebo-controlled, multi-center trial to evaluate the safety and efficacy of oral cladribine versus placebo in the treatment of participants who have sustained a first clinical demyelinating event within 75 days prior to the Screening. Participants must have a minimum of 2 clinically silent lesions on the Screening magnetic resonance imaging (MRI).

The study will include a pre-study evaluation period (Screening period: between 10 and 28 days prior to the start of treatment with blinded study medication (oral cladribine or placebo).

Depending upon the clinical course of their MS, participants will then proceed from the ITP to either the Maintenance Treatment Period (with open-label interferon-beta treatment) or LTFU period (with either open-label low-dose cladribine or no additional treatment (if no progression to MS has been noted after the initial treatment period). The single primary endpoint for the overall study, which will be determined during the ITP, is time to conversion to MS (from randomization), according to the Poser criteria.

For every participants, eligibility for study enrollment and entry into each of the study periods, and diagnosis of conversion to either McDonald MS or CDMS must be confirmed and approved by a Sponsor appointed study Adjudication Committee.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Clinically Isolated Syndrome (CIS)
  • Early MS
  • Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between 18 and 55 years old, inclusive
  • Weighed between 40 to 120 kilogram (kg), inclusive
  • Participant has experienced a single, first clinical event suggestive of MS within 75 days prior to the Screening visit, (clock starts 24 hours after onset). The event must be a new neurological abnormality present for at least 24 hours, either mono- or polysymptomatic
  • Participant has at least two clinically silent lesions on the T2-weighted MRI scan, at screening, with a size of at least 3 millimeter (mm), at least one of which is ovoid or periventricular or infratentorial on screening MRI
  • Participant has EDSS 0 - 5.0 at Screening
  • Participant has no medical history or evidence of latent tuberculosis infection (LTBI) or active tubercular disease, as evidenced by the Mantoux tuberculosis (TB) skin test or a comparable sensitive test according to local regulations/guidelines (if the Mantoux test is not available), and/or a chest X-ray
  • Participant has normal hematological parameters at Screening, as defined by the central laboratory that performed all the assessments
  • If female, she must:

    • be neither pregnant nor breast-feeding, nor attempting to conceive and
    • use a highly effective method of throughout the entire duration of the study and for 90 days following completion of the last dose of study medication. A highly effective method of contraception is defined as those which result in a low failure rate (that is less than 1 percent per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence or vasectomized partner, or
    • be or surgically sterilized (Note: for Danish sites only, participants should use a hormonal contraceptive or intrauterine device for the duration of the trial)
  • Male participants must be willing to use contraception to avoid impregnating partners throughout the study, and for 90 days following the last dose of study medication
  • Be willing and able to comply with study procedures for the duration of the study
  • Participant has to provide written voluntarily, including, for United states of America (USA), participant authorization under Health Insurance Portability and Accountability Act (HIPAA), prior to any study-related procedure that is not part of normal medical care
  • Participant has refused any treatment already available for clinically isolated syndrome (CIS) such as interferons or glatiramer acetate, at the time of entry into the Initial Treatment Period of this study

Exclusion criteria

Exclusion Criteria:

  • Participant has a diagnosis of MS (per McDonald criteria, 2005)
  • Participant has any other disease that could better explain the participant's signs and symptoms
  • Participant has complete transverse myelitis or bilateral optic neuritis
  • Participant using or has used any other approved MS disease modifying drug (DMD)
  • Participant has used any drug or undergone an experimental procedure within 12 weeks prior to Study day 1
  • Participant received oral or systemic or adrenocorticotropic hormone (ACTH) within 30 days prior to screening MRI. The MRI had to be performed 30 days after the oral or systemic corticosteroids or ACTH treatment. In case this interfered with MRI timing the screening period could be extended accordingly.
  • Participant has abnormal total , or (AST) or alanine aminotransferase (ALT) or alkaline phosphatase greater than 2.5 times the
  • Participant suffered from current disease other than MS
  • Participant suffered from psychiatric illness (including history of, or concurrent, severe depressive disorders and/or suicidal ideation) that in the opinion of the investigator creates undue risk to the participant or could affect compliance with the study protocol
  • Participant suffered from major medical illness such as cardiac (for example angina, congestive heart failure or arrhythmia), endocrinologic, hepatic, immunologic, metabolic, renal, pulmonary, gastrointestinal, dermatologic, or other major disease that would preclude the administration of oral cladribine
  • Participant has a history of seizures not adequately controlled by medications
  • Participant has a known allergy to cladribine, interferon-beta, the (s) of the study medications, or to gadolinium- diethylenetriamine penta-acetic acid (DTPA)
  • Participant has any renal condition that would preclude the administration of gadolinium (for example acute or chronic severe renal insufficiency ( [GFR] less than 30 milliliter per minute per 1.73 square meter [mL/min/1.73 m\^2])
  • Participant has a history of chronic or hematological abnormalities
  • Participant has a history of active or chronic infectious disease or any disease that compromises immune function (for example positive [HIV+], human T-lymphotrophic virus [HTLV-1], Lyme disease, latent tuberculosis infection [LTBI] or TB, insulin-dependent diabetes).
  • Participant has previously been screened in this study (signed an ) and then withdrawn
  • Participant has received any immunomodulatory or therapy) at any time prior to Study Day 1, including, but not limited to, the following products: any interferon, glatiramer acetate (Copolymer I), cyclophosphamide, cyclosporine, methotrexate, linomide, azathioprine, mitoxantrone, teriflunomide, laquinimod, cladribine, total lymphoid irradiation, anti-lymphocyte monoclonal antibody treatment (for example natalizumab, alemtuzumab/Campath, anti-cluster of differentiation 4 [CD4]), intravenous immunoglobulin G (IVIG), cytokines or anti-cytokine therapy
  • Participant has received experimental MS treatment
  • Participant has a history of alcohol or drug abuse
  • Participant has intolerance or any to both paracetamol (acetaminophen) and ibuprofen
  • Participant has inability to administer subcutaneous injections either by self or by caregiver
  • Participant has prior or current (with the exception of in situ basal or squamous cell skin cancer surgically removed without recurrence for at least five years)
  • Participant has a positive stool hemoccult test at Screening
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
617 participants (actual)

Study arms

  • Experimental
    Cladribine 5.25 mg/kg (ITP)

    Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 milligrams per kilograms (mg/kg) during the ITP of 96 weeks or until clinically definite multiple sclerosis (CDMS) conversion, whichever occurred first.

    Drug: Cladribine · Drug: Rebif® new formulation (RNF)

  • Experimental
    Cladribine 3.5 mg/kg (ITP)

    Cladribine tablets administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets was administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.

    Drug: Cladribine · Drug: Rebif® new formulation (RNF)

  • Placebo comparator
    Placebo (ITP)

    Placebo matched to cladribine tablets administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occurred first.

    Drug: Placebo · Drug: Rebif® new formulation (RNF)

  • Experimental
    Cladribine 5.25 mg/kg, Rebif (OLMP)

    Participants who received cladribine 5.25 mg/kg and converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received Rebif® new formulation (RNF) subcutaneously at a dose of 44 microgram (mcg) three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.

    Drug: Cladribine · Drug: Rebif® new formulation (RNF)

  • Experimental
    Cladribine 3.5 mg/kg, Rebif (OLMP)

    Participants who received cladribine 3.5 mg/kg and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.

    Drug: Cladribine · Drug: Rebif® new formulation (RNF)

  • Experimental
    Placebo, Rebif (OLMP)

    Participants who received placebo and converted to CDMS during ITP entered in OLMP and received RNF subcutaneously at a dose of 44 mcg three times a week for up to 96 weeks. Due to trial termination, the OLMP duration was reduced for some participants.

    Drug: Placebo

  • Experimental
    Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)

    Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.

    Drug: Cladribine · Drug: Rebif® new formulation (RNF)

  • Experimental
    Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)

    Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.

    Drug: Cladribine · Drug: Rebif® new formulation (RNF)

  • Experimental
    Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)

    Participants who received placebo and did not convert to CDMS during ITP, entered in long-term follow-up (LTFU) period. Participants who converted to McDonald multiple sclerosis (MS) during ITP or during LTFU period received open-label cladribine tablets (3.5 mg/kg) during LTFU period. Participants who converted to CDMS during LTFU received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.

    Drug: Placebo

  • Experimental
    Cladribine 5.25 mg/kg, Rebif (LTFU)

    Participants who received cladribine 5.25 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.

    Drug: Cladribine · Drug: Rebif® new formulation (RNF)

  • Experimental
    Cladribine 3.5 mg/kg, Rebif (LTFU)

    Participants who received cladribine 3.5 mg/kg and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who converted to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.

    Drug: Cladribine · Drug: Rebif® new formulation (RNF)

  • Experimental
    Placebo, Rebif (LTFU)

    Participants who received placebo and did not convert to CDMS during ITP, entered in LTFU period. Participants who did not convert to McDonald MS during ITP did not receive any treatment during LTFU period. Participants who convert to CDMS during LTFU period received RNF subcutaneously at a dose of 44 mcg three times a week for the remaining LTFU period. Under the original study design, total duration of LTFU period was up to 96 weeks. The LTFU duration was reduced due to trial termination. Following the notice of trial termination, no further open label cladribine treatment was administered during the LTFU.

    Drug: Placebo

Interventions

  • Cladribine tablets were administered until CDMS conversion, whichever occur first.

  • DrugPlacebo

    Placebo matched to cladribine tablets were administered.

  • DrugRebif® new formulation (RNF)

    Participants who converted to CDMS during ITP entered in open-label maintenance period (OLMP) and received RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who converted to CDMS during long-term follow-up (LTFU) period, received RNF subcutaneously at a dose of 44 mcg three times a week.

06

What researchers measure

Primary outcomes

  1. ITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS

    CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to Multiple Sclerosis \[MS\]) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months. Kaplan-Meier estimates were provided for of the cumulative (cum.) percentage (%) of participants with CDMS over time. The probability of patients remaining event-free over time (from randomization) in each of the three treatment groups was displayed in the form of survival curves estimated using the non-parametric Kaplan-Meier method.

    Time frame: ITP: Baseline up to Week 96

Secondary outcomes

  1. ITP: Time to Develop Multiple Sclerosis (MS) Conversion According to the Revised McDonald Criteria (2005) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With McDonald MS

    The McDonald criteria use dissemination in time and space established by magnetic resonance imaging (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium enhanced (Gd+) lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions. Kaplan-Meier estimates were provided for the cum. percentage (%) of participants with McDonald MS over time.

    Time frame: ITP: Baseline up to Week 96

  2. ITP: Number of Combined Unique Active (CUA) Lesions, New or Enlarging Time Constant 2 (T2) Lesions, and New or Persisting Time Constant 1 (T1) Gadolinium Enhanced (Gd+) Lesions Per Participant Per Scan

    Number of CUA lesions, new or enlarging T2 lesions, and new or persisting T1 Gd+ lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: ITP: Baseline up to Week 96

  3. OLMP: Time to 3 Month Confirmed Expanded Disability Status Scale (EDSS) Progression From Randomization Represented by Kaplan-Meier Estimates of Probability of Disability Progression

    EDSS progression is based on a standardized neurological exam and focuses on symptoms that commonly occur in Multiple Sclerosis (MS). Overall scores ranges from 0.0 (normal) to 10.0 (death due to MS). A sustained progression on EDSS score was defined as an EDSS progression confirmed into two consecutive assessment. Probability of disability progression at different time points was estimated using Kaplan-Meier method on the time to disability progression defined as the time from randomization to first EDSS increase.

    Time frame: OLMP: Day 1, 90, 180, 270, 360, 450, 540, 630, 720 and 810

  4. LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Multiple Sclerosis (MS) According to the 2005 McDonald Criteria

    The McDonald criteria use dissemination in time and space established by magnetic resonance imaging (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium enhanced (Gd+) lesion found on a repeat MRI.

    Time frame: Time from Randomization up to 1217 days

  5. LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria

    CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months.

    Time frame: Time from Randomization up to 1217 days

  6. LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria

    CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months.

    Time frame: Time from Randomization up to 1217 days

  7. ITP: Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) as Per Poser Criteria

    Clinically definite multiple sclerosis (CDMS) according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months. The percentage of participants who converted to CDMS are reported here.

    Time frame: ITP: Baseline up to week 96

  8. ITP: Percentage of Participants Converting to McDonald Multiple Sclerosis (MS) (2005)

    Percentage of participants converting to mcDonald multiple sclerosis (2005) were reported.

    Time frame: ITP: Baseline up to week 96

  9. ITP: Number of New or Persisting Gd-enhanced Lesions

    Number of new or persisting Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96

  10. OLMP: Number of New or Persisting Gd-enhanced Lesions

    Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: OLMP: Baseline, Week 24, 48, 72 and 96

  11. LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions

    Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: LTFU: Baseline, Week 13, 24 and 36

  12. LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions

    Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: LTFU: Baseline, Week 13, 24, 36 and 48

  13. ITP: Number of New or Enlarging T2 Lesions

    Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96

  14. OLMP: Number of New or Enlarging T2 Lesions

    Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: OLMP: Baseline, Week 24, 48, 72 and 96

  15. LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Enlarging T2 Lesions

    Number of new or enlarging T2 Lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: LTFU: Baseline, Week 13, 24 and 36

  16. LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Enlarging T2 Lesions

    Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: LTFU: Baseline, Week 13, 24, 36 and 48

  17. ITP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions

    Number of CUA lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96

  18. OLMP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions

    Number of combined unique active (CUA) lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: OLMP: Baseline, Week 24, 48, 72 and 96

  19. LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions

    Number of CUA MRI lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: LTFU: Baseline, Week 13, 24 and 36

  20. LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions

    Number of CUA lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: LTFU: Baseline, Week 13, 24, 36 and 48

  21. ITP: Change From Baseline in Volume of T1 Gd-Enhanced Lesions

    Change in volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.

    Time frame: ITP: Baseline, Week 96

  22. OLMP: Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions

    Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.

    Time frame: OLMP: Baseline, Week 24, 48, 72 and 96

  23. LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions

    Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.

    Time frame: LTFU: Baseline, Week 13, 24 and 36

  24. LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions

    Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.

    Time frame: LTFU: Baseline, Week 13, 24, 36 and 48

  25. ITP: Changes From Baseline in Volume of T2 Lesions

    Change in volume of T2 lesions from baseline was measured by using magnetic resonance imaging (MRI) scans.

    Time frame: ITP: Baseline, Week 48 and 96

  26. OLMP: Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions

    Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.

    Time frame: OLMP: Baseline, Week 48 and 96

  27. LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T2 Lesions

    Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.

    Time frame: LTFU: Baseline (Day 1)

  28. LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions

    Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.

    Time frame: Baseline, Week 48

  29. ITP: Number of T1 Hypointense Lesions

    Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: ITP: Baseline, Week 48 and 96

  30. OLMP: Number of T1 Hypointense Lesions

    Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: OLMP: Baseline, Week 48 and 96

  31. LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of T1 Hypointense Lesions

    Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: LTFU: Baseline (Day 1)

  32. LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of T1 Hypointense Lesions

    Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.

    Time frame: LTFU: Baseline, Week 48

  33. ITP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions

    T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.

    Time frame: ITP: Baseline up to Week 96

  34. OLMP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions

    T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.

    Time frame: OLMP: Baseline up to Week 96

  35. LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions

    T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.

    Time frame: LTFU: Baseline up to Week 48

  36. LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions

    T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.

    Time frame: Baseline up to Week 48

  37. ITP: Percentage of Participants With no New or Enlarging T2 Lesions

    T2 lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or enlarging T2 lesions were reported.

    Time frame: ITP: Baseline up to Week 96

  38. OLMP: Percentage of Participants With no New or Enlarging T2 Lesions

    T2 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or enlarging T2 Lesions were reported.

    Time frame: OLMP: Baseline up to 96

  39. LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions

    Enlarging T2 Lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no New or Enlarging T2 Lesions were reported.

    Time frame: Baseline up to Week 48

  40. LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions

    Enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no New or Enlarging T2 lesions were reported.

    Time frame: LTFU: Baseline up to Week 48

  41. ITP: Percent Change From Baseline in Brain Volume

    Brain volume was measured by using magnetic resonance imaging (MRI) scans. Percent change from baseline in brain volume at Week 48 and 96 was reported.

    Time frame: ITP: Baseline, Week 48 and 96

  42. OLMP: Percent Change From Baseline in Brain Volume

    Brain volume was measured by using magnetic resonance imaging (MRI) scans. Percent change from baseline in brain volume at Week 48 and 96 was reported.

    Time frame: OLMP: Baseline, Week 48 and 96

  43. OLMP: Number of Relapses

    Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.

    Time frame: Baseline up to Week 96

  44. LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Relapses

    Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.

    Time frame: Baseline up to Week 48

  45. LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Relapses

    Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.

    Time frame: Baseline up to Week 48

  46. OLMP: Annualized Relapse Rate

    The annualized relapse rate for each treatment group was the mean of the annualized relapse rates for all the participants in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25. Where, Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.

    Time frame: Baseline up to Week 96

  47. OLMP: Percentage of Relapse-Free Participants

    Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Percentage of relapse-free participants were reported.

    Time frame: Baseline up to Week 96

  48. ITP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. Number of Participants with TEAEs and serious TEAEs were reported.

    Time frame: ITP: Baseline up to Week 96

07

Results

Posted Oct 10, 2013

Participant flow

A total of 617 participants were randomized for initial treatment period (ITP) and 616 participants received study drug.

ITP- Treatment Disposition
Participant flow — ITP- Treatment Disposition
MilestoneCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)Cladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
Started205206206000000000
Treated204206206000000000
Completed104131104000000000
Not completed10175102000000000
Withdrew: Adverse event20105000000000
Withdrew: Lost to follow-up002000000000
Withdrew: Randomized but not treated100000000000
Withdrew: Converted to cdms302771000000000
Withdrew: Other503824000000000
OLMP (Up to 96 Weeks)
Participant flow — OLMP (Up to 96 Weeks)
MilestoneCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)Cladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
Started000242560000000
Completed000627000000
Not completed000182353000000
Withdrew: Adverse event000225000000
Withdrew: Death000010000000
Withdrew: Lost to follow-up000100000000
Withdrew: Disease progression000004000000
Withdrew: Other000152044000000
LTFU (Cladribine Treatment) (48 Weeks)
Participant flow — LTFU (Cladribine Treatment) (48 Weeks)
MilestoneCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)Cladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
Started0000009917000
Completed000000000000
Not completed0000009917000
Withdrew: Adverse event000000010000
Withdrew: Lost to follow-up000000001000
Withdrew: Other0000009816000
LTFU (No Cladribine) (48 Weeks)
Participant flow — LTFU (No Cladribine) (48 Weeks)
MilestoneCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)Cladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
Started000000000343614
Completed000000000000
Not completed000000000343614
Withdrew: Other000000000343614

Outcome measures

PrimaryITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS

CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to Multiple Sclerosis \[MS\]) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months. Kaplan-Meier estimates were provided for of the cumulative (cum.) percentage (%) of participants with CDMS over time. The probability of patients remaining event-free over time (from randomization) in each of the three treatment groups was displayed in the form of survival curves estimated using the non-parametric Kaplan-Meier method.

Time frame:
ITP: Baseline up to Week 96
Reported as:
Number · Cum. % of participants with CDMS
ITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS
Cum. % of participants with CDMSCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
ITP: Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS15.814.037.8
Statistical analysis
  • Cladribine 5.25 mg/kg (ITP) vs Placebo (ITP) · two-sided Wald test · p = <0.0001 (The treatment effect was also assessed by hazard ratios using the Cox's proportional hazards model.) · Hazard ratio (hr): 0.381 · 95% CI 0.248 to 0.584
  • Cladribine 3.5 mg/kg (ITP) vs Placebo (ITP) · two-sided Wald test · p = < 0.0001 (The treatment effect was also assessed by hazard ratios using the Cox's proportional hazards model.) · Hazard ratio (hr): 0.327 · 95% CI 0.210 to 0.509
SecondaryITP: Time to Develop Multiple Sclerosis (MS) Conversion According to the Revised McDonald Criteria (2005) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With McDonald MS

The McDonald criteria use dissemination in time and space established by magnetic resonance imaging (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium enhanced (Gd+) lesion found on a repeat MRI. Dissemination in space is established by the presence of any 3 of the following: 1 Gd+ lesion or 9 T2 bright lesions if there is no enhancement; greater than or equal to 1 infratentorial lesion; greater than or equal to 1 juxtacortical lesion; greater than or equal to 3 periventricular lesions. Kaplan-Meier estimates were provided for the cum. percentage (%) of participants with McDonald MS over time.

Time frame:
ITP: Baseline up to Week 96
Reported as:
Number · Cum. % of participants with McDonald MS
ITP: Time to Develop Multiple Sclerosis (MS) Conversion According to the Revised McDonald Criteria (2005) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With McDonald MS
Cum. % of participants with McDonald MSCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
ITP: Time to Develop Multiple Sclerosis (MS) Conversion According to the Revised McDonald Criteria (2005) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With McDonald MS51.3656.0587.14
Statistical analysis
  • Cladribine 5.25 mg/kg (ITP) vs Placebo (ITP) · two-sided Wald test · p = < 0.0001 (The treatment effect was also assessed by hazard ratios using the Cox's proportional hazards model.) · Hazard ratio (hr): 0.425 · 95% CI 0.331 to 0.547
  • Cladribine 3.5 mg/kg (ITP) vs Placebo (ITP) · two-sided Wald test · p = < 0.0001 (The treatment effect was also assessed by hazard ratios using the Cox's proportional hazards model.) · Hazard ratio (hr): 0.497 · 95% CI 0.390 to 0.633
SecondaryITP: Number of Combined Unique Active (CUA) Lesions, New or Enlarging Time Constant 2 (T2) Lesions, and New or Persisting Time Constant 1 (T1) Gadolinium Enhanced (Gd+) Lesions Per Participant Per Scan

Number of CUA lesions, new or enlarging T2 lesions, and new or persisting T1 Gd+ lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
ITP: Baseline up to Week 96
Reported as:
Mean · Lesions
ITP: Number of Combined Unique Active (CUA) Lesions, New or Enlarging Time Constant 2 (T2) Lesions, and New or Persisting Time Constant 1 (T1) Gadolinium Enhanced (Gd+) Lesions Per Participant Per Scan
LesionsCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
CUA lesions1.20 ± 5.790.65 ± 1.802.13 ± 2.87
New or persisting T1 Gd+ lesions0.61 ± 5.330.29 ± 0.970.97 ± 1.62
New or enlarging T2 lesions0.62 ± 1.900.40 ± 1.121.17 ± 1.87
Statistical analysis
  • Cladribine 3.5 mg/kg (ITP) vs Placebo (ITP) · ANCOVA · p = <0.0001 · Median difference (final values): -0.667 · 95% CI -0.971 to -0.500
  • Cladribine 5.25 mg/kg (ITP) vs Placebo (ITP) · ANCOVA · p = <0.0001 · Median difference (final values): -0.625 · 95% CI -0.857 to -0.429
  • Cladribine 3.5 mg/kg (ITP) vs Placebo (ITP) · ANCOVA · p = <0.0001 · Median difference (final values): -0.286 · 95% CI -0.333 to -0.167
  • Cladribine 5.25 mg/kg (ITP) vs Placebo (ITP) · ANCOVA · p = <0.0001 · Median difference (final values): -0.286 · 95% CI -0.375 to -0.167
  • Cladribine 3.5 mg/kg (ITP) vs Placebo (ITP) · ANCOVA · p = <0.0001 · Median difference (final values): -0.333 · 95% CI -0.500 to -0.167
  • Cladribine 5.25 mg/kg (ITP) vs Placebo (ITP) · ANCOVA · p = <0.0001 · Median difference (final values): -0.286 · 95% CI -0.429 to -0.143
SecondaryOLMP: Time to 3 Month Confirmed Expanded Disability Status Scale (EDSS) Progression From Randomization Represented by Kaplan-Meier Estimates of Probability of Disability Progression

EDSS progression is based on a standardized neurological exam and focuses on symptoms that commonly occur in Multiple Sclerosis (MS). Overall scores ranges from 0.0 (normal) to 10.0 (death due to MS). A sustained progression on EDSS score was defined as an EDSS progression confirmed into two consecutive assessment. Probability of disability progression at different time points was estimated using Kaplan-Meier method on the time to disability progression defined as the time from randomization to first EDSS increase.

Time frame:
OLMP: Day 1, 90, 180, 270, 360, 450, 540, 630, 720 and 810
Reported as:
Number · Probability of Disability Progression
OLMP: Time to 3 Month Confirmed Expanded Disability Status Scale (EDSS) Progression From Randomization Represented by Kaplan-Meier Estimates of Probability of Disability Progression
Probability of Disability ProgressionCladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)
Day 10.0000 (0.0000 to 0.0000)0.0000 (0.0000 to 0.0000)0.0000 (0.0000 to 0.0000)
Day 900.0000 (0.0000 to 0.0000)0.0000 (0.0000 to 0.0000)0.0000 (0.0000 to 0.0000)
Day 1800.0417 (-0.0383 to 0.1216)0.0417 (-0.0383 to 0.1216)0.0527 (-0.0054 to 0.1108)
Day 2700.0417 (-0.0383 to 0.1216)0.0417 (-0.0383 to 0.1216)0.0527 (-0.0054 to 0.1108)
Day 3600.0417 (-0.0383 to 0.1216)0.0417 (-0.0383 to 0.1216)0.0527 (-0.0054 to 0.1108)
Day 4500.0417 (-0.0383 to 0.1216)0.0417 (-0.0383 to 0.1216)0.0764 (0.0035 to 0.1492)
Day 5400.0417 (-0.0383 to 0.1216)0.0417 (-0.0383 to 0.1216)0.1094 (0.0147 to 0.2041)
Day 6300.0417 (-0.0383 to 0.1216)0.0417 (-0.0383 to 0.1216)0.1094 (0.0147 to 0.2041)
Day 7200.0417 (-0.0383 to 0.1216)0.0417 (-0.0383 to 0.1216)0.1094 (0.0147 to 0.2041)
SecondaryLTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Multiple Sclerosis (MS) According to the 2005 McDonald Criteria

The McDonald criteria use dissemination in time and space established by magnetic resonance imaging (MRI) findings to provide a clinical diagnosis for MS. Dissemination in time is established by a new time constant 2 (T2) or gadolinium enhanced (Gd+) lesion found on a repeat MRI.

Time frame:
Time from Randomization up to 1217 days
Reported as:
Number · Days
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Multiple Sclerosis (MS) According to the 2005 McDonald Criteria
DaysCladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Multiple Sclerosis (MS) According to the 2005 McDonald Criteria773——
SecondaryLTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria

CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months.

Time frame:
Time from Randomization up to 1217 days
Reported as:
Number · Days
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria
DaysCladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria773——
SecondaryLTFU (LTFU Analysis Set [Treated at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria

CDMS according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months.

Time frame:
Time from Randomization up to 1217 days
Reported as:
Number · Days
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria
DaysCladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Time to Conversion to Clinically Definite Multiple Sclerosis (CDMS) According to Poser Criteria——767
SecondaryITP: Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) as Per Poser Criteria

Clinically definite multiple sclerosis (CDMS) according to the Poser criteria is defined as the occurrence of a second attack or a sustained increase in the expanded disability status scale (EDSS) Score. EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. Sustained EDSS progression was defined as an increase in the EDSS score of greater than or equal to (\>=) 1 point if baseline EDSS was between \>= 1.0 and less than or equal to (=\<) 4.5; or \>= 1.5 points if baseline EDSS was 0, or \>= 0.5 if baseline EDSS \>= 5.0 over a period of at least 3 months. The percentage of participants who converted to CDMS are reported here.

Time frame:
ITP: Baseline up to week 96
Reported as:
Number · Percentage of participants
ITP: Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) as Per Poser Criteria
Percentage of participantsCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
ITP: Percentage of Participants Converting to Clinically Definite Multiple Sclerosis (CDMS) as Per Poser Criteria28.823.156.3
SecondaryITP: Percentage of Participants Converting to McDonald Multiple Sclerosis (MS) (2005)

Percentage of participants converting to mcDonald multiple sclerosis (2005) were reported.

Time frame:
ITP: Baseline up to week 96
Reported as:
Number · Percentage of participants
ITP: Percentage of Participants Converting to McDonald Multiple Sclerosis (MS) (2005)
Percentage of participantsCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
ITP: Percentage of Participants Converting to McDonald Multiple Sclerosis (MS) (2005)70.771.691.8
SecondaryITP: Number of New or Persisting Gd-enhanced Lesions

Number of new or persisting Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96
Reported as:
Mean · Lesions
ITP: Number of New or Persisting Gd-enhanced Lesions
LesionsCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
Week 130.86 ± 5.600.37 ± 1.521.00 ± 1.98
Week 240.03 ± 0.200.13 ± 0.510.92 ± 1.69
Week 360.08 ± 0.380.14 ± 0.440.74 ± 1.28
Week 480.02 ± 0.130.27 ± 0.920.87 ± 1.81
Week 600.10 ± 0.840.22 ± 0.940.74 ± 1.61
Week 720.05 ± 0.530.16 ± 0.810.90 ± 1.88
Week 840.02 ± 0.130.32 ± 2.620.60 ± 1.20
Week 960.07 ± 0.430.18 ± 0.840.64 ± 1.25
SecondaryOLMP: Number of New or Persisting Gd-enhanced Lesions

Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
OLMP: Baseline, Week 24, 48, 72 and 96
Reported as:
Mean · Lesions
OLMP: Number of New or Persisting Gd-enhanced Lesions
LesionsCladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)
Baseline1.38 ± 5.520.88 ± 1.801.27 ± 2.58
Week 240.17 ± 0.480.05 ± 0.210.11 ± 0.56
Week 480.07 ± 0.240.00 ± 0.000.20 ± 0.50
Week 721.50 ± 3.280.13 ± 0.350.33 ± 1.18
Week 961.58 ± 2.690.00 ± 0.000.07 ± 0.26
SecondaryLTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions

Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
LTFU: Baseline, Week 13, 24 and 36
Reported as:
Mean · Lesions
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions
LesionsCladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)
Baseline0.00 ± 0.000.00 ± 0.000.71 ± 1.16
Week 130.00 ± 0.000.00 ± 0.000.13 ± 0.34
Week 240.00 ± 0.000.00 ± 0.000.18 ± 0.40
Week 360.00 ± 0.000.00 ± 0.000.00 ± 0.00
SecondaryLTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions

Number of new or persisting Gd-Enhanced lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
LTFU: Baseline, Week 13, 24, 36 and 48
Reported as:
Mean · Lesions
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Persisting Gd-enhanced Lesions
LesionsCladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
Baseline0.00 ± 0.000.06 ± 0.230.14 ± 0.36
Week 130.00 ± 0.000.07 ± 0.230.09 ± 0.30
Week 240.00 ± 0.000.00 ± 0.000.20 ± 0.45
Week 360.00 ± 0.000.00 ± 0.000.17 ± 0.29
Week 480.00——
SecondaryITP: Number of New or Enlarging T2 Lesions

Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96
Reported as:
Mean · Lesions
ITP: Number of New or Enlarging T2 Lesions
LesionsCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
Week 131.56 ± 3.521.25 ± 3.331.43 ± 2.56
Week 240.24 ± 0.950.20 ± 0.661.01 ± 1.70
Week 360.09 ± 0.400.12 ± 0.421.14 ± 1.87
Week 480.07 ± 0.500.32 ± 2.521.04 ± 1.54
Week 600.13 ± 0.630.25 ± 1.090.71 ± 1.57
Week 720.03 ± 0.220.10 ± 0.340.83 ± 1.77
Week 840.09 ± 0.460.28 ± 2.030.61 ± 1.31
Week 960.04 ± 0.250.10 ± 0.590.38 ± 0.85
SecondaryOLMP: Number of New or Enlarging T2 Lesions

Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
OLMP: Baseline, Week 24, 48, 72 and 96
Reported as:
Mean · Lesions
OLMP: Number of New or Enlarging T2 Lesions
LesionsCladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)
Baseline0.29 ± 0.751.54 ± 6.722.13 ± 7.29
Week 240.26 ± 0.690.43 ± 1.350.68 ± 1.10
Week 480.32 ± 0.650.38 ± 1.090.41 ± 0.71
Week 720.95 ± 1.850.25 ± 0.460.97 ± 1.69
Week 962.00 ± 3.520.67 ± 1.150.47 ± 1.06
SecondaryLTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Enlarging T2 Lesions

Number of new or enlarging T2 Lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
LTFU: Baseline, Week 13, 24 and 36
Reported as:
Mean · Lesions
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of New or Enlarging T2 Lesions
LesionsCladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)
Baseline0.00 ± 0.000.00 ± 0.000.71 ± 1.53
Week 130.00 ± 0.000.25 ± 0.462.06 ± 4.25
Week 240.00 ± 0.000.00 ± 0.000.00 ± 0.00
Week 360.00 ± 0.000.00 ± 0.000.10 ± 0.32
SecondaryLTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Enlarging T2 Lesions

Number of new or enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
LTFU: Baseline, Week 13, 24, 36 and 48
Reported as:
Mean · Lesions
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of New or Enlarging T2 Lesions
LesionsCladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
Baseline0.00 ± 0.000.03 ± 0.170.07 ± 0.27
Week 130.00 ± 0.000.04 ± 0.210.18 ± 0.40
Week 240.00 ± 0.000.13 ± 0.350.00 ± 0.00
Week 360.00 ± 0.000.00 ± 0.000.33 ± 0.58
Week 480.00——
SecondaryITP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions

Number of CUA lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
ITP: Week 13, 24, 36, 48, 60, 72, 84 and 96
Reported as:
Mean · Lesions
ITP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions
LesionsCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
Week 132.37 ± 6.871.56 ± 4.042.41 ± 3.89
Week 240.26 ± 1.030.29 ± 0.891.91 ± 2.93
Week 360.16 ± 0.710.25 ± 0.701.84 ± 2.64
Week 480.09 ± 0.590.56 ± 3.051.89 ± 2.78
Week 600.23 ± 1.400.42 ± 1.871.44 ± 2.70
Week 720.08 ± 0.720.22 ± 1.031.66 ± 3.05
Week 840.11 ± 0.510.55 ± 4.521.14 ± 1.95
Week 960.11 ± 0.600.23 ± 1.390.99 ± 1.89
SecondaryOLMP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions

Number of combined unique active (CUA) lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
OLMP: Baseline, Week 24, 48, 72 and 96
Reported as:
Mean · Lesions
OLMP: Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions
LesionsCladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)
Baseline0.63 ± 1.172.17 ± 7.723.23 ± 8.07
Week 240.42 ± 1.020.48 ± 1.400.79 ± 1.33
Week 480.39 ± 0.810.38 ± 1.090.61 ± 1.02
Week 722.45 ± 5.010.38 ± 0.741.30 ± 2.71
Week 963.33 ± 6.030.67 ± 1.150.53 ± 1.25
SecondaryLTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions

Number of CUA MRI lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
LTFU: Baseline, Week 13, 24 and 36
Reported as:
Mean · Lesions
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions
LesionsCladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)
Baseline0.00 ± 0.000.00 ± 0.001.24 ± 2.49
Week 130.00 ± 0.000.00 ± 0.002.19 ± 4.46
Week 240.00 ± 0.000.25 ± 0.460.18 ± 0.40
Week 360.00 ± 0.000.00 ± 0.000.10 ± 0.32
SecondaryLTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions

Number of CUA lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
LTFU: Baseline, Week 13, 24, 36 and 48
Reported as:
Mean · Lesions
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Combined Unique Active (CUA) Magnetic Resonance Imaging (MRI) Lesions
LesionsCladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
Baseline0.00 ± 0.000.03 ± 0.170.14 ± 0.36
Week 130.00 ± 0.000.04 ± 0.210.18 ± 0.40
Week 240.00 ± 0.000.13 ± 0.350.00 ± 0.00
Week 360.00 ± 0.000.00 ± 0.000.33 ± 0.58
Week 480.00——
SecondaryITP: Change From Baseline in Volume of T1 Gd-Enhanced Lesions

Change in volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.

Time frame:
ITP: Baseline, Week 96
Reported as:
Mean · cubic millimeters (mm^3)
ITP: Change From Baseline in Volume of T1 Gd-Enhanced Lesions
cubic millimeters (mm^3)Cladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
ITP: Change From Baseline in Volume of T1 Gd-Enhanced Lesions-73.97 ± 204.80-126.64 ± 399.3948.63 ± 239.03
Statistical analysis
  • Cladribine 3.5 mg/kg (ITP) vs Placebo (ITP) · ANCOVA · p = <0.0001 · Point estimate: -1.700 · 95% CI -37.200 to 0.000
  • Cladribine 5.25 mg/kg (ITP) vs Placebo (ITP) · ANCOVA · p = <0.0001 · Point estimate: -28.600 · 95% CI -117.300 to 0.000
SecondaryOLMP: Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions

Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.

Time frame:
OLMP: Baseline, Week 24, 48, 72 and 96
Reported as:
Mean · mm^3
OLMP: Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions
mm^3Cladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)
Baseline91.06 ± 368.98113.64 ± 248.74136.61 ± 344.31
Week 247.71 ± 26.353.48 ± 16.709.14 ± 55.62
Week 485.22 ± 19.750.00 ± 0.0039.00 ± 188.80
Week 72219.52 ± 377.8556.86 ± 160.8325.85 ± 96.18
Week 96330.20 ± 442.020.00 ± 0.0022.51 ± 87.17
Change at Week 24-87.30 ± 379.50-120.04 ± 250.42-134.67 ± 343.19
Change at Week 48-106.82 ± 415.70-146.62 ± 298.86-116.06 ± 429.90
Change at Week 7226.00 ± 600.82-155.91 ± 341.97-192.24 ± 439.11
Change at Week 96275.83 ± 360.07-391.93 ± 523.92-247.76 ± 593.34
SecondaryLTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions

Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.

Time frame:
LTFU: Baseline, Week 13, 24 and 36
Reported as:
Mean · mm^3
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions
mm^3Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)
Baseline0.00 ± 0.000.00 ± 0.0079.43 ± 143.64
Week 130.00 ± 0.000.00 ± 0.0020.56 ± 70.96
Week 240.00 ± 0.000.00 ± 0.0025.23 ± 66.24
Week 360.00 ± 0.000.00 ± 0.000.00 ± 0.00
Change at Week 130.00 ± 0.000.00 ± 0.00-63.83 ± 147.43
Change at Week 240.00 ± 0.000.00 ± 0.00-32.25 ± 113.96
Change at Week 360.00 ± 0.000.00 ± 0.00-58.93 ± 85.19
SecondaryLTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions

Volume of T1 Gd-Enhanced lesions was measured by using magnetic resonance imaging (MRI) scans.

Time frame:
LTFU: Baseline, Week 13, 24, 36 and 48
Reported as:
Mean · mm^3
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T1 Gd-Enhanced Lesions and Changes From Baseline in Volume of T1 Gd-Enhanced Lesions
mm^3Cladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
Baseline0.00 ± 0.004.45 ± 21.2527.79 ± 76.02
Week 130.00 ± 0.007.34 ± 27.7617.43 ± 57.80
Week 240.00 ± 0.000.00 ± 0.0057.22 ± 127.95
Week 360.00 ± 0.000.00 ± 0.0057.22 ± 99.10
Week 480.00——
Change at Week 130.00 ± 0.000.38 ± 1.32-17.95 ± 41.38
Change at Week 240.00 ± 0.00-2.48 ± 9.60-20.60 ± 57.89
Change at Week 360.00 ± 0.00-5.31 ± 14.06-31.48 ± 54.53
Change at Week 480.00——
SecondaryITP: Changes From Baseline in Volume of T2 Lesions

Change in volume of T2 lesions from baseline was measured by using magnetic resonance imaging (MRI) scans.

Time frame:
ITP: Baseline, Week 48 and 96
Reported as:
Mean · mm^3
ITP: Changes From Baseline in Volume of T2 Lesions
mm^3Cladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
Baseline3825.73 ± 5093.523435.22 ± 5184.123436.69 ± 4613.43
Change at Week 48-654.20 ± 2061.85-828.97 ± 3513.04-29.57 ± 2581.44
Change at Week 96-1237.44 ± 2718.76-1605.63 ± 2889.61-886.39 ± 2955.44
SecondaryOLMP: Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions

Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.

Time frame:
OLMP: Baseline, Week 48 and 96
Reported as:
Mean · mm^3
OLMP: Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions
mm^3Cladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)
Baseline398.88 ± 1102.27630.70 ± 1707.241019.30 ± 2872.03
Week 48767.66 ± 1875.86458.13 ± 984.12508.97 ± 1159.97
Week 962606.15 ± 5542.810.00 ± 0.00647.17 ± 1345.62
Change at Week 48523.27 ± 2065.54-20.20 ± 2025.21-77.67 ± 1760.20
Change at Week 962245.18 ± 5810.530.00 ± 0.00255.39 ± 1352.80
SecondaryLTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T2 Lesions

Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.

Time frame:
LTFU: Baseline (Day 1)
Reported as:
Mean · mm^3
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T2 Lesions
mm^3Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Mean Volume of T2 Lesions1217.53 ± 1991.21587.79 ± 1491.20702.30 ± 1254.66
SecondaryLTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions

Volume of T2 lesions was measured by using magnetic resonance imaging (MRI) scans.

Time frame:
Baseline, Week 48
Reported as:
Mean · mm^3
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Mean Volume of T2 Lesions and Changes From Baseline in Volume of T2 Lesions
mm^3Cladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
Baseline1402.08 ± 1799.96962.26 ± 1026.991407.75 ± 1890.94
Week 480.00——
Change at Week 48-969.90——
SecondaryITP: Number of T1 Hypointense Lesions

Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
ITP: Baseline, Week 48 and 96
Reported as:
Mean · Lesions
ITP: Number of T1 Hypointense Lesions
LesionsCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
Baseline8.0 ± 11.77.3 ± 12.27.0 ± 8.6
Week 488.39 ± 12.606.95 ± 12.867.07 ± 8.75
Week 965.35 ± 8.143.82 ± 6.895.06 ± 6.82
SecondaryOLMP: Number of T1 Hypointense Lesions

Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
OLMP: Baseline, Week 48 and 96
Reported as:
Mean · Lesions
OLMP: Number of T1 Hypointense Lesions
LesionsCladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)
Baseline0.92 ± 2.222.32 ± 9.521.45 ± 3.53
Week 483.79 ± 8.321.00 ± 2.850.74 ± 1.83
Week 960.50 ± 0.840.00 ± 0.001.47 ± 2.80
SecondaryLTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of T1 Hypointense Lesions

Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
LTFU: Baseline (Day 1)
Reported as:
Mean · Lesions
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of T1 Hypointense Lesions
LesionsCladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of T1 Hypointense Lesions4.44 ± 7.251.22 ± 3.312.24 ± 5.01
SecondaryLTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of T1 Hypointense Lesions

Number of T1 Hypointense lesions were measured by using magnetic resonance imaging (MRI) scans.

Time frame:
LTFU: Baseline, Week 48
Reported as:
Mean · Lesions
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of T1 Hypointense Lesions
LesionsCladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
Baseline5.74 ± 8.213.53 ± 5.782.93 ± 4.46
Week 484.50——
SecondaryITP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions

T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.

Time frame:
ITP: Baseline up to Week 96
Reported as:
Number · Percentage of Participants
ITP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions
Percentage of ParticipantsCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
ITP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions67.057.121.6
SecondaryOLMP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions

T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.

Time frame:
OLMP: Baseline up to Week 96
Reported as:
Number · Percentage of participants
OLMP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions
Percentage of participantsCladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)
OLMP: Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions25.050.035.3
SecondaryLTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions

T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.

Time frame:
LTFU: Baseline up to Week 48
Reported as:
Number · Percentage of Participants
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions
Percentage of ParticipantsCladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions000
SecondaryLTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions

T1 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or persisting T1 Gd-enhanced lesions were reported.

Time frame:
Baseline up to Week 48
Reported as:
Number · Percentage of participants
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions
Percentage of participantsCladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Persisting T1 Gd-Enhanced Lesions000
SecondaryITP: Percentage of Participants With no New or Enlarging T2 Lesions

T2 lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or enlarging T2 lesions were reported.

Time frame:
ITP: Baseline up to Week 96
Reported as:
Number · Percentage of Participants
ITP: Percentage of Participants With no New or Enlarging T2 Lesions
Percentage of ParticipantsCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
ITP: Percentage of Participants With no New or Enlarging T2 Lesions32.935.119.0
SecondaryOLMP: Percentage of Participants With no New or Enlarging T2 Lesions

T2 Gd-enhanced lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no new or enlarging T2 Lesions were reported.

Time frame:
OLMP: Baseline up to 96
Reported as:
Number · Percentage of participants
OLMP: Percentage of Participants With no New or Enlarging T2 Lesions
Percentage of participantsCladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)
OLMP: Percentage of Participants With no New or Enlarging T2 Lesions18.216.713.5
SecondaryLTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions

Enlarging T2 Lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no New or Enlarging T2 Lesions were reported.

Time frame:
Baseline up to Week 48
Reported as:
Number · Percentage of Participants
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions
Percentage of ParticipantsCladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions000
SecondaryLTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions

Enlarging T2 lesions were measured by using magnetic resonance imaging (MRI) scans. Percentage of participants with no New or Enlarging T2 lesions were reported.

Time frame:
LTFU: Baseline up to Week 48
Reported as:
Number · Percentage of participants
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions
Percentage of participantsCladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Percentage of Participants With no New or Enlarging T2 Lesions000
SecondaryITP: Percent Change From Baseline in Brain Volume

Brain volume was measured by using magnetic resonance imaging (MRI) scans. Percent change from baseline in brain volume at Week 48 and 96 was reported.

Time frame:
ITP: Baseline, Week 48 and 96
Reported as:
Mean · Percent change
ITP: Percent Change From Baseline in Brain Volume
Percent changeCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
Week 48-0.47 ± 0.63-0.48 ± 0.69-0.33 ± 0.76
Week 96-0.59 ± 0.80-0.72 ± 0.73-0.75 ± 0.65
SecondaryOLMP: Percent Change From Baseline in Brain Volume

Brain volume was measured by using magnetic resonance imaging (MRI) scans. Percent change from baseline in brain volume at Week 48 and 96 was reported.

Time frame:
OLMP: Baseline, Week 48 and 96
Reported as:
Mean · Percent change
OLMP: Percent Change From Baseline in Brain Volume
Percent changeCladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)
Week 48-0.41 ± 0.98-1.60 ± 1.40-0.56 ± 1.11
Week 960.06 ± 1.36—-1.31 ± 0.76
SecondaryOLMP: Number of Relapses

Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.

Time frame:
Baseline up to Week 96
Reported as:
Mean · Relapses
OLMP: Number of Relapses
RelapsesCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
OLMP: Number of Relapses0.33 ± 0.640.16 ± 0.370.55 ± 1.00
SecondaryLTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Relapses

Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.

Time frame:
Baseline up to Week 48
Reported as:
Mean · Relapses
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Relapses
RelapsesCladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)
LTFU (LTFU Analysis Set [Treated at LTFU Entry]): Number of Relapses0.00 ± 0.000.00 ± 0.000.06 ± 0.24
SecondaryLTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Relapses

Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.

Time frame:
Baseline up to Week 48
Reported as:
Mean · Relapses
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Relapses
RelapsesCladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
LTFU (LTFU Analysis Set [No Treatment at LTFU Entry]): Number of Relapses0.03 ± 0.170.03 ± 0.170.00 ± 0.00
SecondaryOLMP: Annualized Relapse Rate

The annualized relapse rate for each treatment group was the mean of the annualized relapse rates for all the participants in the group, calculated as the total number of confirmed relapses divided by the total number of days on study multiplied by 365.25. Where, Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days.

Time frame:
Baseline up to Week 96
Reported as:
Number · relapses per year
OLMP: Annualized Relapse Rate
relapses per yearCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
OLMP: Annualized Relapse Rate0.24 (0.07 to 0.40)0.14 (0.00 to 0.27)0.42 (0.28 to 0.56)
SecondaryOLMP: Percentage of Relapse-Free Participants

Relapse was defined as new, worsening or recurrent neurological symptoms attributed to multiple sclerosis that last for at least 24 hours without fever or infection, or adverse reaction to prescribed medication, preceded by a stable or improving neurological status of at least 30 days. Percentage of relapse-free participants were reported.

Time frame:
Baseline up to Week 96
Reported as:
Number · Percentage of participants
OLMP: Percentage of Relapse-Free Participants
Percentage of participantsCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
OLMP: Percentage of Relapse-Free Participants40.020.030.8
SecondaryITP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition. The term TEAE is defined as AEs starting or worsening after the first intake of the study drug. TEAEs include both Serious TEAEs and non-serious TEAEs. Number of Participants with TEAEs and serious TEAEs were reported.

Time frame:
ITP: Baseline up to Week 96
Reported as:
Count of participants · Participants
ITP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)
TEAEs165168162
Serious TEAEs122322

Adverse events

Collected over ITP: Baseline up to 96 weeks; OLMP: Baseline up to 96 weeks; LTFU: Baseline up to 48 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cladribine 5.25 mg/kg (ITP)0/204 (0%)12/204 (5.9%)133/204 (65.2%)
Cladribine 3.5 mg/kg (ITP)0/206 (0%)23/206 (11.2%)132/206 (64.1%)
Placebo (ITP)0/206 (0%)22/206 (10.7%)116/206 (56.3%)
Cladribine 5.25 mg/kg, Rebif (OLMP)0/24 (0%)1/24 (4.2%)18/24 (75%)
Cladribine 3.5 mg/kg, Rebif (OLMP)1/25 (4%)4/25 (16%)19/25 (76%)
Placebo, Rebif (OLMP)0/60 (0%)5/60 (8.3%)41/60 (68.3%)
Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)0/9 (0%)0/9 (0%)3/9 (33.3%)
Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)0/9 (0%)0/9 (0%)4/9 (44.4%)
Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)0/16 (0%)1/16 (6.3%)7/16 (43.8%)
Cladribine 5.25 mg/kg, Rebif (LTFU)0/34 (0%)0/34 (0%)2/34 (5.9%)
Cladribine 3.5 mg/kg, Rebif (LTFU)0/36 (0%)1/36 (2.8%)0/36 (0%)
Placebo, Rebif (LTFU)0/14 (0%)0/14 (0%)2/14 (14.3%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)Cladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
Blood creatine phosphokinase increasedInvestigations3/2047/2064/2061/240/250/600/90/91/160/340/360/14
Cardio-respiratory arrestCardiac disorders0/2040/2060/2060/241/250/600/90/90/160/340/360/14
HyperprolactinaemiaEndocrine disorders0/2040/2060/2060/241/250/600/90/90/160/340/360/14
Gastric ulcer perforationGastrointestinal disorders0/2040/2060/2060/241/250/600/90/90/160/340/360/14
Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2040/2060/2060/241/250/600/90/90/160/340/360/14
Nasal cystRespiratory, thoracic and mediastinal disorders0/2040/2060/2060/241/250/600/90/90/160/340/360/14
Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2040/2060/2060/240/250/600/90/90/160/341/360/14
Blood uric acid increasedInvestigations0/2040/2061/2060/240/251/600/90/90/160/340/360/14
Injection site necrosisGeneral disorders0/2040/2060/2060/240/251/600/90/90/160/340/360/14
ErysipelasInfections and infestations0/2040/2060/2060/240/251/600/90/90/160/340/360/14
Most frequent other events
Showing 10 of 51
Most frequent other events
EventCladribine 5.25 mg/kg (ITP)Cladribine 3.5 mg/kg (ITP)Placebo (ITP)Cladribine 5.25 mg/kg, Rebif (OLMP)Cladribine 3.5 mg/kg, Rebif (OLMP)Placebo, Rebif (OLMP)Cladribine 5.25 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 3.5 mg/kg, Rebif, Cladribine 3.5 mg/kg (LTFU)Placebo, Rebif, Cladribine 3.5 mg/kg (LTFU)Cladribine 5.25 mg/kg, Rebif (LTFU)Cladribine 3.5 mg/kg, Rebif (LTFU)Placebo, Rebif (LTFU)
PharyngitisInfections and infestations12/20410/20612/2062/249/253/600/90/90/160/340/360/14
Influenza like illnessGeneral disorders0/2040/2060/2067/249/2521/600/90/90/160/340/360/14
HeadacheNervous system disorders58/20464/20657/2065/248/2510/601/90/93/162/340/360/14
LymphopeniaBlood and lymphatic system disorders47/20425/2060/2062/241/252/600/91/90/160/340/360/14
PyrexiaGeneral disorders0/2040/2060/2061/245/255/600/90/90/160/340/360/14
NasopharyngitisInfections and infestations36/20435/20638/2062/241/255/600/91/90/160/340/360/14
FatigueGeneral disorders15/20415/20619/2063/240/251/600/90/90/160/340/360/14
Upper respiratory tract infectionInfections and infestations23/20421/20617/2060/240/250/601/90/92/160/340/360/14
MyalgiaMusculoskeletal and connective tissue disorders0/2040/2060/2063/240/257/600/90/90/160/340/360/14
NauseaGastrointestinal disorders23/20424/20619/2061/241/253/600/90/90/160/340/360/14

Baseline characteristics

The intent-to-treat (ITT) population included all randomized participants who received at least 1 dose of ITP study medication (cladribine or placebo).

Age, Continuous
Age, Continuous(years)Cladribine 5.25 mg/kgCladribine 3.5 mg/kgPlaceboTotal
Mean31.9 ± 8.831.7 ± 9.232.2 ± 8.231.9 ± 8.7
Age, Customized
Age, Customized(Participants)Cladribine 5.25 mg/kgCladribine 3.5 mg/kgPlaceboTotal
Greater than or equal to 30 years111110113334
Less than 30 years939693282
Sex: Female, Male
Sex: Female, Male(Participants)Cladribine 5.25 mg/kgCladribine 3.5 mg/kgPlaceboTotal
Female132130138400
Male727668216
Expanded disability status scale (EDSS) score
Expanded disability status scale (EDSS) score(units on scale)Cladribine 5.25 mg/kgCladribine 3.5 mg/kgPlaceboTotal
Mean1.6 ± 0.91.6 ± 0.91.7 ± 0.91.6 ± 0.9
Number of Time Constant 1 (T1) Gadolinium Enhanced (GD+) lesions
Number of Time Constant 1 (T1) Gadolinium Enhanced (GD+) lesions(lesions)Cladribine 5.25 mg/kgCladribine 3.5 mg/kgPlaceboTotal
Mean1.9 ± 5.81.5 ± 4.50.9 ± 2.51.4 ± 4.5
Number of T2 Lesions
Number of T2 Lesions(lesions)Cladribine 5.25 mg/kgCladribine 3.5 mg/kgPlaceboTotal
Mean29.7 ± 29.626.8 ± 28.326.3 ± 27.427.6 ± 28.4
Time from First Demyelinating Event to Randomization
Time from First Demyelinating Event to Randomization(Days)Cladribine 5.25 mg/kgCladribine 3.5 mg/kgPlaceboTotal
Mean79.35 ± 17.6178.67 ± 15.9779.40 ± 17.9479.14 ± 17.17
Monofocal/Multifocal Classification (By Adjudication Committee)
Monofocal/Multifocal Classification (By Adjudication Committee)(Participants)Cladribine 5.25 mg/kgCladribine 3.5 mg/kgPlaceboTotal
Monofocal108112101321
Multifocal9694105295

2 further baseline measures are reported on the registry.

08

Study locations

158 sites
  • Hope Research Institute Medical Plaza LLC Desert Hills
    Phoenix, Arizona, United States
  • Multiple Sclerosis Center Drive, Neurology Suite 701
    Newport Beach, California, United States
  • University of Colorado at Denver Health Sciences
    Denver, Colorado, United States
  • Fort Collins Neurology
    Fort Collins, Colorado, United States
  • MS Center of Brevard MIMA Centry Research Associates
    Melbourne, Florida, United States
  • University of South Florida
    Tampa, Florida, United States
  • MS Center of Atlanta
    Atlanta, Georgia, United States
  • Bruce Hughes West Building
    Des Moines, Iowa, United States
  • Michigan Neurology Associates
    Clinton Township, Michigan, United States
  • Henry Ford Hospital
    Detroit, Michigan, United States
  • University of Minnesota
    Minneapolis, Minnesota, United States
  • Dennis Dietrich
    Great Falls, Montana, United States
  • University of Medicine and Dentistry of New Jersey School of Neurology
    Stratford, New Jersey, United States
  • Upstate Clinical Research LLC 3
    Albany, New York, United States
  • Neurological Specialists of Long Island
    Great Neck, New York, United States
  • Multiple Sclerosis Center of Northeastern NY
    New York, New York, United States
  • Comprehensive MS Care Clinic at South Shore Multiple Sclerosis
    Patchogue, New York, United States
  • Carolinas Medical Center
    Charlotte, North Carolina, United States
  • Meritcare Neuroscience Center Neurology
    Fargo, North Dakota, United States
  • University of Cincinnati
    Cincinnati, Ohio, United States
  • MS Center of Oklahoma
    Oklahoma City, Oklahoma, United States
  • Neurology and Sleep Medicine
    Bethlehem, Pennsylvania, United States
  • Swedish Medical Center Cherry Hill
    Seattle, Washington, United States
  • Neurology & Neurological Association of Tacoma
    Tacoma, Washington, United States
  • Instituto Medico Rodriguez Alfici
    Godoy Cruz, Argentina
  • Fundacion Rosarina de Neurorehabilitacion
    Rosario, Argentina
  • Krankenhaus der Barmherzigen Brüder
    Linz, Austria
  • Algemeen Ziekenhuis St Jan
    Brugge, Belgium
  • Cliniques Universitaires St-Luc
    Brussels, Belgium
  • Hopital Erasme
    Bruxelles, Belgium
  • CHU de Liege - Domaine Universitaire du Sart Tilman,
    Liège, Belgium
  • Clinical Center University of Sarajevo
    Sarajevo, Bosnia and Herzegovina
  • Military Medical Academy- Sofia (MMA)
    Pleven, Bulgaria
  • MBAL Rousse AD 1st
    Rousse, Bulgaria
  • Central Clinic Hospital
    Sofia, Bulgaria
  • Military Medical Academy
    Sofia, Bulgaria
  • National Heart Hospital
    Sofia, Bulgaria
  • Second MHAT
    Sofia, Bulgaria
  • Tokuda Hospital
    Sofia, Bulgaria
  • University Hospital St Naum
    Sofia, Bulgaria
  • Medical Centre Centromed 2000
    Veliko Tarnovo, Bulgaria
  • Ottawa General Hospital
    Ottawa, Canada
  • General Hospital Varazdin
    Varazdin, Croatia
  • University Hospital Zagreb
    Zagreb, Croatia
  • Faculty Hospital Brno
    Brno, Czechia
  • Neurological dept of Faculty
    Hradec Kralove, Czechia
  • Fakultní nemocnice s poliklinikou Ostrava
    Ostrava, Czechia
  • Faculty Hospital Motol
    Prague, Czechia
  • Klinika Vseobecne
    Prague, Czechia
  • Nemocnice Teplice
    Teplice, Czechia
  • East Tallinn Central Hospital
    Tallinn, Estonia
  • West Tallinn Central Hospital
    Tallinn, Estonia
  • HUS Hyvinkaa Central Hospital
    Hyvinkaa, Finland
  • OYKS Neurologian Klinikka
    Oulu, Finland
  • Neurologian Klinikka Seinajoen Keskussairaala
    Seinajoki, Finland
  • Tampere University Hospital
    Tampere, Finland
  • Turun Yliopistollinen Keskussairaala Rakennus 3 1
    Turku, Finland
  • CHU de Lille
    Lille Cedex, France
  • CHU de Nantes
    Nantes, France
  • American Memorial Hospital
    Reims Cedex, France
  • David Tatishvili Medical Center
    Tbilisi, Georgia
  • Medical Center Health
    Tbilisi, Georgia
  • S. Khechinashvili Tbilisi State Medical University
    Tbilisi, Georgia
  • Universitaetsklinikum und Medizinische Fakultaet Heidelberg
    Heidelberg, Germany
  • Philipps-Universitaet Marburg
    Marburg, Germany
  • M S Ramaiah Medical College Hospital
    Bangalore, Karnataka, India
  • St.John's Medical College and Hospital
    Bangalore, Karnataka, India
  • Amrita Institute of Medical Sciences and Research
    Kochi, Kerala, India
  • Kovai Medical Centre and Hospital
    Coimbatore, India
  • Sanjay Gandhi Post Graduate Institute of Medical Sciences
    Lucknow, India
  • Mallikatta Neuro and Research Centre
    Mangalore, India
  • Ospedale Regionale Torrette
    Ancona, Italy
  • Università de Bari
    Bari, Italy
  • Ospedale Binaghi Centro Sclerosi Multipla
    Cagliari, Italy
  • Azienda Ospedaliera Garibaldi
    Catania, Italy
  • Dipartimento di Neuroscienze
    Catania, Italy
  • Università G. D'Annunzio
    Chieti, Italy
  • Ospedale San Antonio Abate
    Gallarate, Italy
  • Universita degli Studi di Genova
    Genova, Italy
  • Ospedale e casa di riposo P. Richiedei
    Gussago, Italy
  • Ospedale San Raffaele
    Milano, Italy
  • Dipartimento di Scienze Neurologiche
    Napoli, Italy
  • Azienda Sanitaria Ospedaliera San Luigi Gonzaga
    Orbassano, Italy
  • Villa Sofia Hospital Azienda Ospedaliera Villa Sofia P.zza Salerno e Resuttana 1
    Palermo, Italy
  • Istituto Neurologico C. Mondino
    Pavia, Italy
  • Azienda Ospedaliera S. Camillo Forlanini
    Roma, Italy
  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
    Roma, Italy
  • Università di Roma La Sapienza
    Roma, Italy
  • National Cancer Center, Department of Neurology,
    Gyeonggi-do, Korea, Republic of
  • Department of Neurology, 50 Ilwon-dong, Gangnam-gu
    Seoul, Korea, Republic of
  • Department of Neurology, Asan Medical Center, 388-1 Pungnap 2-dong, Songpa-gu
    Seoul, Korea, Republic of
  • Seoul National University Hospital, Department of Neurology
    Seoul, Korea, Republic of
  • Yonsei University Medical Center, Department of Neurology, Yonsei University Medical Center
    Seoul, Korea, Republic of
  • American University of Beirut
    Beirut, Lebanon
  • Clinic of Neurology "Klinicki Centar"
    Skopje, North Macedonia
  • Helse Bergen HF Kvinneklinikken Haukeland Universitetssykehus Jonas
    Bergen, Norway
  • Regionsykehuset I Trondheim, Nevrologisk avd.
    Trondheim, Norway
  • 10 Wojskowy Szpital Kliniczny
    Bydgoszcz, Poland
  • Wojewodzki Szpital Specjalistyczny im. M. Kopernika
    Gdansk, Poland
  • Niepubliczny Zespol Opieki Zdrowotnej
    Krakow, Poland

Showing the first 100 of 158 sites across 34 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Oh J, Walker B, Giovannoni G, Jack D, Dangond F, Nolting A, Aldridge J, Lebson LA, Leist TP. Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary. Neurodegener Dis Manag. 2022 Feb 1;12(1):1-7. doi: 10.2217/nmt-2021-0041. Epub 2022 Jan 12. PubMed 35019731 ↗
  • Giovannoni G, Coyle PK, Vermersch P, Walker B, Aldridge J, Nolting A, Galazka A, Lemieux C, Leist TP. Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets. Front Immunol. 2021 Dec 24;12:763433. doi: 10.3389/fimmu.2021.763433. eCollection 2021. PubMed 35003076 ↗
  • Giovannoni G, Galazka A, Schick R, Leist T, Comi G, Montalban X, Damian D, Dangond F, Cook S. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. Drug Saf. 2020 Jul;43(7):635-643. doi: 10.1007/s40264-020-00948-x. PubMed 32447743 ↗
  • Freedman MS, Leist TP, Comi G, Cree BA, Coyle PK, Hartung HP, Vermersch P, Damian D, Dangond F. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. Mult Scler J Exp Transl Clin. 2017 Oct 9;3(4):2055217317732802. doi: 10.1177/2055217317732802. eCollection 2017 Oct-Dec. PubMed 29051829 ↗
  • Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M; oral cladribine for early MS (ORACLE MS) Study Group. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014 Mar;13(3):257-67. doi: 10.1016/S1474-4422(14)70005-5. Epub 2014 Feb 4. PubMed 24502830 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2008 to primary completion in Jul 2011, 31 months.

Results were first posted in Oct 2013, 2 years 2 months after primary completion.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 31 months is below that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2008
First posted
Jul 31, 2008
StartActual
Dec 31, 2008
Primary completionActual
Jul 31, 2011
CompletionActual
Apr 30, 2012
Results first posted
Oct 10, 2013
Last update
Mar 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00725985
Responsible party
Sponsor
First posted
Jul 31, 2008
Start date
Dec 31, 2008
Primary completion
Jul 31, 2011
Completion
Apr 30, 2012
Results posted
Oct 10, 2013
Last update
Mar 22, 2021

Study contacts

Bettina Stubinski, MD
study director · Merck Serono S.A., Geneva

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cladribine

Start the discussion